Increased aggregation of human platelets produced by advanced glycation end products in vitro

Misako Hangaishi, Junichi Taguchi, Toshio Miyata, Yuji Ikari, Masako Togo, Yoshiaki Hashimoto, Tsuyoshi Watanabe, Satoshi Kimura, Kiyoshi Kurokawa, Minoru Ohno

Research output: Contribution to journalArticlepeer-review

55 Citations (Scopus)


Advanced glyco-oxidation end products (AGEs) generate oxygen free radicals that potentiate the development of atherosclerosis. Thus, AGEs may potentiate the aggregation of human platelets through oxidative stress. AGE-bovine serum albumin (BSA) and AGE-poly-L-lysine were evaluated for aggregation of human platelets. Superoxide in platelet-rich plasma (PRP) was measured using lucigenin-derived chemiluminescence. The platelet aggregation induced by ADP or U46619 was potentiated by preincubation with AGE-BSA, by 40% and by 59%, P < .05, respectively, vs BSA. Aggregation was increased by AGEs in a dose-dependent manner. The production of superoxide was significantly greater in PRP incubated with AGE-BSA vs BSA. The other Maillard reaction products, such as Amadori-, pentosidine-, and carboxymethyl lysine (CML)-BSA had no effect. Superoxide dismutase or indomethacin abolished the enhancing effect of AGEs on the platelet aggregation. AGEs potentiate platelet aggregation possibly with superoxide anions and prostanoids. AGE-induced potentiation of platelet aggregation may be involved in the development of atherosclerosis.

Original languageEnglish
Pages (from-to)285-292
Number of pages8
JournalBiochemical and biophysical research communications
Issue number2
Publication statusPublished - 1998 Jul 20
Externally publishedYes

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Increased aggregation of human platelets produced by advanced glycation end products in vitro'. Together they form a unique fingerprint.

Cite this